|
CREBZF expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.05602201930333E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.27110005748921E-10 |
| Normal-vs-Stage2 |
2.24189999897817E-08 |
| Normal-vs-Stage3 |
2.12785344899658E-12 |
| Normal-vs-Stage4 |
6.92120000200802E-08 |
| Stage1-vs-Stage2 |
1.636200E-01 |
| Stage1-vs-Stage3 |
2.478000E-02 |
| Stage1-vs-Stage4 |
2.223400E-01 |
| Stage2-vs-Stage3 |
8.171400E-01 |
| Stage2-vs-Stage4 |
8.864600E-01 |
| Stage3-vs-Stage4 |
6.856000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.5349501104065E-12 |
| Normal-vs-AfricanAmerican |
4.410000E-04 |
| Normal-vs-Asian |
1.205720E-04 |
| Caucasian-vs-AfricanAmerican |
5.347400E-01 |
| Caucasian-vs-Asian |
1.319030E-01 |
| AfricanAmerican-vs-Asian |
6.777400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.77159994744159E-09 |
| Normal-vs-Female |
1.95388150103781E-12 |
| Male-vs-Female |
5.643800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.1829988058123E-11 |
| Normal-vs-Age(41-60Yrs) |
5.13169950977499E-10 |
| Normal-vs-Age(61-80Yrs) |
2.49799958496055E-10 |
| Normal-vs-Age(81-100Yrs) |
2.245500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.178400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.090760E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.927580E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.356000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.668000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.828600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.23050000025538E-07 |
| Classical-VS-Follicular |
1.344200E-01 |
| Classical-VS-Other |
4.405000E-01 |
| Classical-VS-Normal |
4.19880019641994E-10 |
| Tall-VS-Follicular |
3.362000E-03 |
| Tall-VS-Other |
6.091700E-02 |
| Tall-VS-Normal |
1.67332814271504E-12 |
| Follicular-VS-Other |
2.443600E-01 |
| Follicular-VS-Normal |
4.09510003684943E-09 |
| Other-VS-Normal |
1.116210E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.85640391947572E-11 |
| Normal-vs-N1 |
7.215300E-04 |
| N0-vs-N1 |
1.008990E-01 |
|
|
